Trial Profile
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Elismetrep (Primary)
- Indications Vasomotor symptoms
- Focus Adverse reactions
- Sponsors Mitsubishi Tanabe Pharma America
- 09 Feb 2017 Status changed from recruiting to completed.
- 27 Jun 2016 Status changed from not yet recruiting to recruiting.
- 21 Jun 2016 New trial record